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Summary 
Therapeutic applications of monoclonal antibodies 
(in oncologic indications) 
Background 
Monoclonal antibodies (Mab) are one of the possible means of treating oncological 
diseases. This thesis aims to summarize basic information about them 
and provide an overview of all antitumour monoclonal antibodies registered in 
the Czech Republic, whose stage III studies had been concluded before 
December 31, 2008. 
Main findings 
An overview of concluded stage three studies of all registered indications 
for seven tumour antibodies have been created including alemtuzumab, 
bevacizumab, 
cetuximab, ibritumomab tiuxetan, panitumumab, rituximab and trastuzumab. 
Considering the brief use of Mab in the medical practice, many of the studies 
have not been finished or their results are still to be published. 
Judging from the overview, the scope of indication of some monoclonal 
antibodies rises depending on the duration of their use. At the beginnings of 
therapeutic use, mainly for ethical reasons, monoclonal antibodies were applied 
to patients with later stages of the disease. The increasing amount of information 
on effectiveness and safety of the treatment as part of the research has enabled 
the use of biological treatment in earlier stages of tumour diseases and 
also in the adjuvant therapy. In comparison with the existing chemotherapy, 
Mab have often demonstrated better therapeutic effects. Greater effectiveness 
together with a lower number of untoward effects play a major role in improving 
the patients‘ quality of life. 
Conclusion 
Introducing monoclonal antibodies into the therapy of tumour diseases have 
signalled a turning point in their treatment. At present, the main problem regarding 
the monoclonal antibidies is their high price and the constant search for the 
ways in which they could be included in the therapeutic practice. 
